(Q35916968)

11 August 2017

0 references

Defining the critical hurdles in cancer immunotherapy (English)

1 reference

11 August 2017

1 reference

100

Laurence Zitvogel

0 references

Guido Kroemer

51

Guido Kroemer

0 references

Kunle Odunsi

66

Kunle Odunsi

0 references

Jérôme Galon

27

Jerome Galon

0 references

James P. Allison

5

James P Allison

0 references

Dainius Characiejus

Dainius Characiejus

18

0 references

Enrico Proietti

Enrico Proietti

74

0 references

Mohamed L. Salem

Mohamed L Salem

82

0 references

Jonathan L Bramson

Jonathan L Bramson

13

0 references

Lisa H. Butterfield

Lisa H Butterfield

3

0 references

George Coukos

George Coukos

20

0 references

Andrea Nicolini

Andrea Nicolini

64

0 references

Christian H. Ottensmeier

Christian Ottensmeier

70

0 references

Michele Maio

Michele Maio

56

0 references

Graham Pawelec

Graham Pawelec

73

0 references

Per thor Straten

Per Thor Straten

89

0 references

Pamela Ohashi

Pamela S Ohashi

67

0 references

Licia Rivoltini

Licia Rivoltini

80

0 references

Harry Dolstra

23

Harry Dolstra

1 reference

11 August 2017

Brad Nelson

63

0 references

Paolo Antonio Ascierto

6

Paolo Antonio Ascierto

1 reference

11 August 2017

29

Cécile Gouttefangeas

1 reference

11 August 2017

40

Elizabeth M Jaffee

1 reference

11 August 2017

98

Jedd D Wolchok

1 reference

11 August 2017

84

Barbara Seliger

1 reference

11 August 2017

Giuseppe Masucci

59

0 references

Michele Guida

Michele Guida

31

0 references

Hiroshi Shiku

Hiroshi Shiku

86

0 references

Ignacio Melero, MD-PhD

60

Ignacio Melero

1 reference

11 August 2017

77

Antoni Ribas

1 reference

11 August 2017

42

Carl H June

1 reference

11 August 2017

102

Francesco M Marincola

1 reference

11 August 2017

38

Patrick Hwu

1 reference

11 August 2017

103

Thomas F Gajewski

1 reference

11 August 2017

35

F Stephen Hodi

1 reference

11 August 2017

1

Bernard A Fox

1 reference

11 August 2017

37

Christoph Huber

1 reference

11 August 2017

79

Gerd Ritter

1 reference

11 August 2017

69

Lloyd J Old

1 reference

11 August 2017

85

Padmanee Sharma

1 reference

11 August 2017

48

Samir N Khleif

1 reference

11 August 2017

7

Michael B Atkins

1 reference

11 August 2017

54

Michael T Lotze

1 reference

11 August 2017

94

Ena Wang

1 reference

11 August 2017

49

Rolf Kiessling

1 reference

11 August 2017

72

Giorgio Parmiani

1 reference

11 August 2017

4

Steinar Aamdal

1 reference

11 August 2017

14

Cedrik M Britten

1 reference

11 August 2017

17

Alfred E Chang

1 reference

11 August 2017

21

Tanja de Gruijl

1 reference

11 August 2017

22

Robert O Dillman

1 reference

11 August 2017

24

Glenn Dranoff

1 reference

11 August 2017

30

Fabio Grizzi

1 reference

11 August 2017

32

Leif Håkansson

1 reference

11 August 2017

41

Sylvia Janetzki

1 reference

11 August 2017

43

Pawel Kalinski

1 reference

11 August 2017

50

Beatrix Kotlan

1 reference

11 August 2017

55

Cristina Maccalli

1 reference

11 August 2017

Michael J Mastrangelo

58

Michael J Mastrangelo

1 reference

11 August 2017

65

Michael I Nishimura

1 reference

11 August 2017

Jill O'Donnell-Tormey

68

Jill O'Donnell-Tormey

1 reference

11 August 2017

78

Ruggero Ridolfi

1 reference

11 August 2017

Harpreet Singh-Jasuja

87

Harpreet Singh-Jasuja

1 reference

11 August 2017

90

Hideaki Tahara

1 reference

11 August 2017

91

Zhigang Tian

1 reference

11 August 2017

Sjoerd H van der Burg

92

Sjoerd H van Der Burg

1 reference

11 August 2017

96

Hauke Winter

1 reference

11 August 2017

101

Heinz Zwierzina

1 reference

11 August 2017

104

Jon M Wigginton

1 reference

11 August 2017

105

Mary L Disis

1 reference

11 August 2017

36

Axel Hoos

1 reference

11 August 2017

62

William J Murphy

0 references

author name string

Dolores J Schendel

2

1 reference

11 August 2017

Jirina Bartunkova

8

1 reference

11 August 2017

Lothar Bergmann

9

1 reference

11 August 2017

Neil Berinstein

10

1 reference

11 August 2017

Cristina C Bonorino

11

1 reference

11 August 2017

Ernest Borden

12

1 reference

11 August 2017

Xuetao Cao

15

1 reference

11 August 2017

William E Carson

16

1 reference

11 August 2017

A Raja Choudhury

19

1 reference

11 August 2017

Lindy G Durrant

25

1 reference

11 August 2017

James H Finke

26

1 reference

11 August 2017

Jared A Gollob

28

1 reference

11 August 2017

Kristen Hege

33

1 reference

11 August 2017

Ronald B Herberman

34

1 reference

11 August 2017

Kohzoh Imai

39

1 reference

11 August 2017

Howard L Kaufman

44

1 reference

11 August 2017

Koji Kawakami

45

1 reference

11 August 2017

Yutaka Kawakami

46

1 reference

11 August 2017

Ulrich Keilholtz

47

1 reference

11 August 2017

Rejean Lapointe

52

1 reference

11 August 2017

Hyam I Levitsky

53

1 reference

11 August 2017

Jens-Peter Marschner

57

1 reference

11 August 2017

Cornelius Melief

61

1 reference

11 August 2017

Michael Papamichail

71

1 reference

11 August 2017

Shukui Qin

75

1 reference

11 August 2017

Robert Rees

76

1 reference

11 August 2017

Pedro J Romero

81

1 reference

11 August 2017

Rik J Scheper

83

1 reference

11 August 2017

Wenru Song

88

1 reference

11 August 2017

Paul von Hoegen

93

1 reference

11 August 2017

Marij Jp Welters

95

1 reference

11 August 2017

Tara Withington

97

1 reference

11 August 2017

Weihua Xiao

99

1 reference

11 August 2017

14 December 2011

1 reference

Journal of Translational Medicine

11 August 2017

1 reference

11 August 2017

9

1 reference

11 August 2017

214

1 reference

Creative Commons Attribution 2.0 Generic

11 August 2017

start time

1 December 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1479-5876-9-214

0 references

cites work

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Immune parameters affecting the efficacy of chemotherapeutic regimens

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Cells of origin in cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

TNM staging in colorectal cancer: T is for T cell and M is for memory.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

A new era: melanoma genetics and therapeutics

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Genetic instability influences drug response in cancer cells.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Improved endpoints for cancer immunotherapy trials

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Dual roles for immunity in gastrointestinal cancers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

New models for cancer research: human cancer stem cell xenografts.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

The road we must take: multidisciplinary team science

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Assessing oncologic benefit in clinical trials of immunotherapy agents

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Melanoma from bench to bedside: meeting report from the 6th international melanoma congress.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

"MIATA"-minimal information about T cell assays

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Immunotherapeutics in development for prostate cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Translational Research Working Group developmental pathway for immune response modifiers.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

MIFlowCyt: the minimum information about a Flow Cytometry Experiment

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Targeted therapies to improve tumor immunotherapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

The anticancer immune response: indispensable for therapeutic success?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Stromal gene expression predicts clinical outcome in breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Twelve immunotherapy drugs that could cure cancers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Sensors of ionizing radiation effects on the immunological microenvironment of cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

A clinical development paradigm for cancer vaccines and related biologics

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Adaptive immunity maintains occult cancer in an equilibrium state

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Identification of clinically useful cancer prognostic factors: what are we missing?

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

A methodological framework to enhance the clinical success of cancer immunotherapy

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3338100

Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines

24 September 2018

1 reference

12 December 2020

The impact of harmonization on ELISPOT assay performance

1 reference

12 December 2020

Immunotherapy and chemotherapy--a practical partnership

1 reference

12 December 2020

Science careers. Carving a career in translational research

1 reference

12 December 2020

Identifiers

DOI

10.1186/1479-5876-9-214

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

PubMed publication ID

22168571

1 reference